Eagle Pharmaceuticals Inc (EGRX.OQ)
EGRX.OQ on NASDAQ Stock Exchange Global Market
55.01USD
24 Apr 2018
55.01USD
24 Apr 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$55.01
$55.01
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
96,610
96,610
52-wk High
$97.14
$97.14
52-wk Low
$45.05
$45.05
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2017 | Dec '17 | 46.78 | 0.801 |
| Sep '17 | 63.02 | 0.979 | |
| Jun '17 | 50.11 | 0.280 | |
| Mar '17 | 76.79 | 1.418 | |
| FY 2016 | Dec '16 | 81.14 | 3.530 |
| Sep '16 | 37.83 | 0.727 | |
| Jun '16 | 40.92 | 0.796 | |
| Mar '16 | 29.59 | -0.057 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 4 | 50.79 | 55.15 | 47.00 | 66.70 |
| Quarter Ending Sep-18 | 4 | 50.05 | 51.20 | 47.39 | 86.00 |
| Year Ending Dec-18 | 4 | 201.06 | 205.70 | 189.90 | 268.96 |
| Year Ending Dec-19 | 4 | 220.98 | 235.80 | 210.30 | 343.83 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 4 | 1.00 | 1.08 | 0.92 | 1.19 |
| Quarter Ending Sep-18 | 4 | 0.96 | 1.15 | 0.75 | 1.78 |
| Year Ending Dec-18 | 4 | 3.70 | 4.06 | 3.27 | 4.30 |
| Year Ending Dec-19 | 4 | 4.18 | 4.53 | 3.96 | 6.48 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 9.78 | 30.95 | 32.74 | |
| P/E High - Last 5 Yrs. | -- | 40.70 | 45.72 | |
| P/E Low - Last 5 Yrs. | -- | 23.63 | 24.22 | |
| Beta | 1.23 | 0.89 | 0.88 | |
| Price to Sales (TTM) | 3.59 | 3.94 | 5.71 | |
| Price to Book (MRQ) | 5.34 | 4.80 | 5.37 | |
| Price to Tangible Book (MRQ) | 9.43 | 5.61 | 6.95 | |
| Price to Cash Flow (TTM) | 8.87 | 22.91 | 23.32 | |
| % Owned Institutions | -- | 1.21 | 2.17 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.56 | 1.50 | |
| Dividend Yield - 5 Year Avg | -- | 1.57 | 1.51 | |
| Dividend 5 Year Growth Rate | -- | 4.47 | 5.32 | |
| Payout Ratio(TTM) | 0.00 | 45.35 | 43.29 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 22.46 | 3.69 | 9.21 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 160.39 | 4.83 | 5.69 | |
| Sales - 5 Yr. Growth Rate | -- | 10.08 | 10.32 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -64.84 | 16.36 | 19.36 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 3,637.76 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 9.87 | 10.76 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 15.52 | 15.47 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 3.76 | 2.12 | 2.19 |
| Current Ratio (MRQ) | 3.88 | 2.90 | 2.98 |
| LT Debt to Equity (MRQ) | 0.00 | 9.88 | 12.18 |
| Total Debt to Equity (MRQ) | 0.00 | 13.86 | 16.45 |
| Interest Coverage (TTM) | -- | 35.89 | 32.81 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 75.17 | 54.81 | 54.44 | |
| Gross Margin - 5 Yr. Avg. | -- | 52.15 | 52.20 | |
| EBITD Margin (TTM) | 33.38 | -- | -- | |
| EBITD - 5 Yr. Avg | -- | 18.57 | 10.96 | |
| Operating Margin (TTM) | 32.21 | 14.36 | 4.73 | |
| Operating Margin - 5 Yr. Avg. | -- | 14.52 | 6.40 | |
| Pre-Tax Margin (TTM) | 32.20 | 14.82 | 5.57 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | 14.90 | 6.81 | |
| Net Profit Margin (TTM) | 39.32 | 11.08 | 1.87 | |
| Net Profit Margin - 5 Yr. Avg. | -- | 11.20 | 3.09 | |
| Effective Tax Rate (TTM) | -22.12 | 23.16 | 23.04 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 23.42 | 23.96 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 3,193,182 | 938,079,949 | 846,830,423 | |
| Net Income/Employee (TTM) | 1,255,584 | 110,368,367 | 99,616,130 | |
| Receivable Turnover (TTM) | 4.67 | 5.63 | 5.78 | |
| Inventory Turnover (TTM) | 12.27 | 2.59 | 3.35 | |
| Asset Turnover (TTM) | 1.33 | 0.95 | 0.92 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 52.32 | 11.40 | 10.95 | |
| Return on Assets - 5 Yr. Avg. | -- | 12.91 | 12.31 | |
| Return on Investment (TTM) | 64.07 | 14.84 | 14.38 | |
| Return on Investment - 5 Yr. Avg. | -- | 16.88 | 16.10 | |
| Return on Equity (TTM) | 70.78 | 16.34 | 16.07 | |
| Return on Equity - 5 Yr. Avg. | -- | 17.98 | 17.39 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 186.11 | -- | -- |
| EPS (TTM) % | 3,033.35 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Eagle Pharmaceuticals Inc
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA
- BRIEF-Eagle Pharmaceuticals - Announced Co's Eagle Biologics Division Has Been Issued A New Patent
- BRIEF-Eagle Pharmaceuticals Reports Q4 EPS Of $0.58
- BRIEF-Iridian Asset Management LLC Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals As Of Dec. 31, 2017 - SEC Filing
- BRIEF-Iridian Asset Management Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals
Institutional Holders
| % Shares Owned: | 0.00% |
| # of Holders: | 244 |
| Total Shares Held: | 16,734,931 |
| 3 Mo. Net Change: | 122,779 |
| # New Positions: | 6 |
| # Closed Positions: | 3 |
| # Increased Positions: | 11 |
| # Reduced Positions: | 14 |
| # Net Buyers: | -3 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.